This is the environment where digital transformation with AI and smart contract engineering becomes genuinely consequential rather than aspirational. The question for life science consulting teams and enterprise technology leaders isn’t whether pharma needs modernization. It’s whether the architecture chosen will be interoperable, privacy-first, and built for the complexity of multi-stakeholder workflows. The sections ahead examine where the pain concentrates and how purpose-built digital solutions are beginning to change the calculus.
Clinical research challenges
Getting a drug from lab to shelf takes years. And at every stage, the underlying systems struggle to keep up. Clinical research in pharma isn’t just scientifically complex, it’s operationally fractured, running on legacy platforms that weren’t built for the scale, speed, or data sensitivity the process demands today.
Take patient recruitment. Once a candidate drug clears early safety assessments, companies must identify, enroll, and retain trial participants, often through third-party intermediaries, while simultaneously collecting dosage data, managing billing, and tracking side effects across two distinct study phases. Data integrity risks compound at every handoff. And retention is never guaranteed.
Patient consent adds another layer. Paper-based signatures, fax transmissions to research coordinators, and fragmented medical histories mean pharmaceutical companies essentially operate on the honor system. No full patient registry exists across segregated healthcare domains. Prior trial participation, pre-existing conditions, drug interactions, none of it surfaces reliably. The cost of getting this wrong isn’t just regulatory. It’s legal exposure, trial invalidation, and patient harm.
Then there’s data distribution. Trial results must reach participants, physicians, sponsors, CROs, ethics committees, and regulatory agencies, each with different access rights, each running different systems. Healthcare interoperability challenges mean this sharing is slow, manual, and prone to error. HIPAA compliance tightens every step further, demanding permissioned data flows in a sector where permissioning has rarely been built in by design.
The deeper issue? Digital transformation with AI and smart data engineering hasn’t yet reached the clinical research function with the same urgency it has claims processing or EHR management. That gap is where real patient risk lives.
Supply Chain Management Challenges
Tracking a drug from raw ingredient to pharmacy shelf sounds straightforward. In practice, it’s one of the most brittle operations in all of life sciences, and the cracks show up in ways that put patients at real risk.
Globalization made active pharmaceutical ingredients cheaper to source and faster to ship across borders. But that same global reach introduced contamination risk at every handoff. When a bad batch enters the chain, pharmaceutical companies have no reliable, unified record to trace it back to its origin. The result: wide-ranging recalls that disrupt patients, burden pharmacies, and expose manufacturers to significant legal liability.
Counterfeit drugs compound the problem. The World Health Organization estimates over $79 billion in counterfeit medicine moves through global supply chains each year, killing approximately 1 million people annually. Bad actors exploit the gaps between disconnected systems, inserting look-alike products precisely where visibility is lowest.
At the center of this is a data problem. Manufacturers, logistics providers, distributors, hospitals, and pharmacies each operate on separate platforms. No single source of truth exists across that network. Confirming a drug’s origin, validating its transit history, or initiating a coordinated recall means manually reconciling data from systems that weren’t designed to talk to each other. For life sciences companies serious about smart clinical trials and digital transformation with AI, this disconnect in supply chain infrastructure is a fundamental gap, one where enterprise AI solutions and modern data engineering can drive real, measurable change in both traceability and recall response time.
Addressing pharma and life sciences challenges through smart contracts
The real problem in pharma isn’t a shortage of data. It’s that the data exists in too many places, owned by too many parties, governed by too many rules, and moved through too many manual handoffs. Patient consent sits in fax machines. Clinical trial results live in disconnected systems. Supply chain records span logistics providers, manufacturers, and regulators who rarely share a common platform. That’s not a technology gap. That’s a structural one.
Smart contracts change the equation. Rather than trying to integrate a patchwork of legacy systems after the fact, they encode the business logic itself: who sees what, who can act on what, and when. Every permissioned party in a drug’s lifecycle, from clinical research coordinators to regulatory agencies to pharmacists, operates within rules defined in code rather than negotiated in spreadsheets.
For pharma and life sciences organizations pursuing digital transformation with AI, this matters precisely because automation only works when the underlying data is trustworthy and the workflow is traceable. A digital transformation consulting approach that skips foundational data integrity will hit the same walls faster. Smart contracts don’t just digitize existing processes. They rebuild the trust architecture those processes depend on. That’s why Brillio sees this as the starting point for meaningful life sciences enterprise AI solutions: fix the multi-party workflow first, and AI has something real to work with.
DAML as a solution to taming complex challenges through digital transformation
Pharma’s real problem isn’t a shortage of data. It’s a shortage of trust between the systems holding it. Patients, providers, CROs, regulators, insurers, and manufacturers all participate in the same drug lifecycle but operate on architectures that were never designed to talk to one another. That disconnect is exactly where digital transformation consulting has historically fallen short: it digitizes processes without resolving the underlying fragmentation.
DAML takes a different approach. Rather than forcing all parties onto a single platform, it models business logic as smart contracts that travel with the transaction itself, defining who can see what, who must authorize what, and what happens next. Every party retains their existing infrastructure. But for the first time, a pharmaceutical company running on a traditional database and a healthcare network running on a distributed ledger can transact with full data integrity and zero ambiguity about rights or obligations.
What makes this genuinely interesting from an enterprise AI solutions standpoint is the abstraction layer. Developers write the application once. DAML handles the distributed logic automatically, so engineering teams focus on clinical and supply chain workflows rather than infrastructure concerns. That’s not a minor efficiency gain. For organizations where a single data error can trigger a drug recall affecting thousands of patients, it’s a foundational shift in how digital transformation with AI gets built and sustained.
And because DAML is vendor-agnostic, it protects future investment. Today’s infrastructure choice doesn’t lock the enterprise into tomorrow’s limitations.
Brillio’s DAML-Driven Clinical Research Solution for a Trial Patient Portal
Patient consent in clinical trials has long been a paper-based problem dressed up as a compliance challenge. Signatures get faxed, data gets siloed, and research teams spend more time reconciling records than analyzing outcomes. That’s the operational reality Brillio set out to change.
The solution centers on a DAML-driven distributed application that acts as an end-to-end trial patient portal. Built on smart contract logic, it captures informed consent, tracks drug consumption patterns, and logs trial outcomes in a single, permissioned environment. No more parallel systems. No more manual aggregation across segregated domains.
What makes this approach genuinely different is its privacy-first architecture. Rights and obligations are encoded directly into the application, so each participant, whether a patient, research coordinator, CRO, or regulatory body, sees only what they’re permitted to see. HIPAA compliance isn’t bolted on; it’s structural.
For enterprise teams navigating the intersection of healthcare data interoperability and smart clinical trials for lifesciences, this matters enormously. The solution deploys on existing databases or distributed ledgers depending on whether data immutability is required, which means infrastructure investment doesn’t dictate the roadmap.
For clinical research teams, the outcomes are measurable: reduced enrollment friction through remote data collection, automated consent tracking at every collection event, certified device identification independent of the trial site, and a verifiable data provenance trail for master file management. Patient engagement in healthcare improves when participants spend less time at clinical sites and more time simply living their lives while the portal captures what research teams need.
Brillio’s DAML-Driven Track and Trace Solution to Speed Up Drug Recalls
Counterfeit medicine is a $79 billion global problem. Over 1 million people die annually from consuming fraudulent drugs, ones with wrong ingredients, no active compounds, or dangerous contaminants slipping through a supply chain that most pharma enterprises still manage on disconnected, legacy systems. That’s not a data problem. It’s a digital transformation problem.
When a recall hits, every minute counts. Manufacturers must halt production, distributors must freeze shipments, pharmacies must pull inventory, and patients must be notified, all simultaneously, across parties who don’t share a common platform. Brillio’s DAML-driven track and trace solution changes that equation by building a single distributed application that connects every participant, from raw ingredient supplier to point of sale, under one permissioned, privacy-first framework.
Each drug carries a unique identifier that travels with it. Manufacturers verify ingredient origin. Logistics providers log transit. Pharmacists confirm arrival. Patients confirm purchase. The moment any node in that network flags contamination or counterfeit activity, every permissioned party is notified and their records update in real time, no phone trees, no fax chains, no data gaps.
And because the underlying architecture runs on a distributed ledger through enterprise AI engineering principles, the solution also trains a machine learning model to detect fraudulent ingredients before they enter production. Faster recalls. Fewer patient health risks. Cleaner audit trails for legal and regulatory bodies. This is what smart clinical trials for lifescience infrastructure looks like when digital transformation with AI is applied where it genuinely matters.
Conclusion
Smart contracts aren’t a future consideration for pharma and life sciences. They’re a present-tense requirement. Clinical research and drug supply chains involve dozens of parties, hundreds of data handoffs, and zero tolerance for error, yet most of the infrastructure holding it together was built for a different era.
What DAML-driven distributed applications make possible is genuinely different from conventional digital transformation consulting approaches: not just faster data movement, but data movement with built-in permissions, provenance, and accountability. Every party sees exactly what they’re authorized to see. Every transaction is traceable. Recalls happen in hours, not weeks. Patient consent isn’t a paper trail, it’s a live, auditable record.
But technology alone isn’t the answer. Pharma organizations need a partner who can assess the clinical research model, identify the supply chain gaps, and build enterprise AI solutions that bridge historically segregated domains without creating new ones. That’s the work Brillio does in life sciences, connecting the distributed logic of modern drug development with the engineering rigor required to make it production-ready.
The path forward starts with two questions: where are your biggest data gaps today, and what would it mean to close them? For most pharmaceutical enterprises, clinical trials and drug tracking are the right place to begin. Get those right, and the broader patient healthcare journey becomes far easier to transform.
